Renaissance Capital logo

MIRA Pharmaceuticals Priced, Nasdaq: MIRA

Preclinical developer of synthetic THC analogs for anxiety and neurologic indications.

Industry: Health Care

Latest Trade: $0.71 0.00 (0.0%)

First Day Return: +6.0%

Return from IPO: -89.9%

Industry: Health Care

We are an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Our target patient population is also typically presenting with chronic pain. Our drug candidate, MIRA1a, if approved by the FDA, may be a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by us, we believe that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain by potentially striking a balance between the beneficial effects of THC and CBD. MIRA1a achieves this by selectively targeting the cannabinoid type 1 (“CB1”) and cannabinoid type 2 (“CB2”) receptors. Cannabinoid receptors, located throughout the body, are part of the endocannabinoid system, which is involved in a variety of physiological processes and responses including appetite, pain-sensation, mood, and memory. With respect to THC, our pre-clinical studies have shown that MIRA1a may have less potency at CB1 but maintains high activation at CB2.
more less
IPO Data
IPO File Date 06/29/2023
Offer Price $7.00
Price Range $7.00 - $7.00
Offer Shares (mm) 1.3
Deal Size ($mm) $9
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 08/02/2023
Offer Price $7.00
Price Range $7.00 - $7.00
Offer Shares (mm) 1.3
Deal Size ($mm) $9
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Kingswood Capital Markets
Company Data
Headquarters Baltimore, MD, United States
Founded 2020
Employees 7
Website www.mirapharmaceuticals.com

MIRA Pharmaceuticals (MIRA) Performance